NCI Moonshot Workshop (virtual)
Enhancing Systemic Drug Delivery in Cancer
April 27-28, 2021
Cancer treatments are continuously improving, however, delivering drugs effectively by controlling their pharmacokinetics and biodistribution still poses significant challenges. Several methods to enhance the delivery and accumulation of drugs at the tumor site have been developed and used with varying success. These methods usually rely on the use of delivery platforms, modification of the tumor microenvironment, or apply companion diagnostic tools to identify individuals who have the potential to respond well to a particular delivery mechanism.
This workshop will provide the opportunities for physicians and researchers working with different cancer treatment modalities and drug delivery strategies to take stock of the current techniques used for enhancement of systemic drug delivery to tumors and to discuss best strategies for the future. We will conduct discussions in two ‘orthogonal’ sessions covering 1) different cancer treatment modalities and their requirements on delivery approaches and 2) available delivery methodologies and their suitability to support current and emerging cancer therapies.
This workshop is organized under Cancer Moonshot initiative which aims to accelerate cancer research and to make more therapies available to more patients. We hope that you will enjoy this important discussion. Its outcomes are expected to aid cancer patients in obtaining better and more comfortable care in the future.
This meeting will be held virtually on April 27-28, 2021. If you would like to attend, please sign-up at:
Confirmed invited speakers (in alphabetical order) include:
Daniel Anderson, PhD, Mass. Institute of Technology (delivery of RNA-based therapeutics)
William Dahut, MD, National Cancer Institute (chemotherapeutics in cancer)
Alberto Gabizon, MD, Hebrew University, Israel (nano-chemotherapeutics in the clinic)
Jordan Green, PhD, Johns Hopkins University (cancer theranostics)
Darrell Irvine, PhD, Mass. Institute of Technology (nanoparticles for immunotherapy)
John Lambert, PhD (antibody-drug-conjugates in cancer therapies)
Laurent Levy, PhD, Nanobiotix, Paris, France (high Z materials for radiation therapy enhancement)
Philip Low, PhD, Purdue University (ligand-targeted drugs)
Marcela Maus, MD, PhD, Mass. General Hospital (cell-based immunotherapies)
Samir Mitragotri, PhD, Harvard University (innovation in drug delivery vehicles)
Zachary Morris, MD, PhD, University of Wisconsin School of Medicine (check point inhibitor immunotherapies)
Andre Nel, MD, PhD, UC Los Angeles (nanoparticles for immunotherapy)
Neeta Pandit-Taskar, MD, Memorial Sloan Kettering (targeted radionuclide therapies)
Anil Sood, MD, MD Anderson Cancer Center (gene therapies)
Workshop Organizing Committee:
Rose Aurigemma, PhD, Developmental Therapeutics Program/Division of Cancer Treatment and Diagnosis/NCI
Piotr Grodzinski, PhD, Cancer Imaging Program/Division of Cancer Treatment and Diagnosis/NCI
Lalitha Shankar, MD, PhD, Cancer Imaging Program/Division of Cancer Treatment and Diagnosis/NCI
Stephan Stern, PhD, Nanotechnology Characterization Lab/Frederick National Laboratory for Cancer Research
Click here to download a pdf of this workshop announcement.